European Expansion Anteris expanded offices to France and Western Europe and secured regulatory clearance to expand the PARADIGM trial in France, signaling Europe market access momentum. This creates sales opportunities with European hospitals, trial sites, distributors, and CRO partners to accelerate DurAVR THV adoption and trial enrollment.

Trial Momentum The company is advancing the PARADIGM trial and has showcased one-year DurAVR THV outcomes, with ongoing expansion in the United States and Europe. Leverage data-driven capabilities and trial infrastructure to offer trial management, data capture, analytics, and outcomes reporting to health systems and payers.

Patient Focus DurAVR THV is a biomimetic valve designed to restore natural heart function and targets younger, more active patients. This creates a compelling case to migrate patients from legacy TAVR devices at high-volume cardiac centers and to pursue education, training, and deployment programs with hospitals.

Regulatory Access Regulatory clearances to expand France and plans to broaden centers across North America and Europe imply a need for regulatory affairs, health economics, and market access support. Position as a partner for payer discussions, reimbursement strategy, and HTA submissions for DurAVR THV.

Growth Partnerships With strong growth signals and leadership expansion, Anteris appears ready for strategic partnerships. Target distributors, CROs, contract manufacturers, and training partners to scale market development, logistics, and adoption of DurAVR THV across regions.